Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed follicular non-Hodgkin lymphoma (NHL) meeting 1 of the following criteria:~  * Bulky (i.e., single mass ≥ 7cm in any uni-dimensional measurement) stage II disease~ * Stage III or IV disease~* WHO grade 1, 2, or 3a disease~* Bone marrow biopsies allowed provided they are submitted in conjunction with nodal biopsies~  * No fine-needle aspirates for diagnosis~* Tumor tissue must express the CD20-positive antigen by flow cytometry or IHC~* At least 1 site of measurable disease that is \> 1 cm in diameter in ≥ 1 dimension present either on physical exam or imaging studies~  * Non-measurable disease alone not allowed, including the following:~    * Bone lesions (lesions if present should be noted)~   * Ascites~   * Pleural/pericardial effusion~   * Lymphangitis cutis/pulmonis~   * Bone marrow (involvement by NHL should be noted)~* Low- or intermediate-risk disease by the Follicular Lymphoma International Prognostic Index (FLIPI)~  * FLIPI score meeting 1 or 2 of the following risk factors:~    * Age \> 60 years~   * Involvement of \> 4 nodal sites~   * Stage III-IV disease~   * Hemoglobin \< 12.0 g/dL~   * LDH normal~ * Risk determined by the following:~    * Low Risk: 0-1 of the above risk factors~   * Intermediate Risk: 2 risk factors~   * Poor Risk: ≥ 3 risk factors~* No known CNS involvement~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,000/μL~* Platelet count ≥ 75,000/μL~* Creatinine clearance ≥ 30 mL/min~* Bilirubin ≤ 2 times upper limit of normal (unless secondary to Gilbert syndrome or hepatic involvement of NHL)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* Patients with HIV infection allowed provided the following criteria are met:~  * No evidence of coinfection with hepatitis B or C~ * CD4+ cell count ≥ 400/mm³~ * No evidence of resistant strains of HIV~ * HIV viral load \< 10,000 copies HIV RNA/mL if not on anti-HIV therapy OR HIV viral load \< 50 copies if on anti-HIV therapy~ * No history of AIDS-defining conditions~* No evidence of active hepatitis B (HBV) or C (HCV) infection (i.e., no positive serology for anti-HBc or anti-HCV antibodies)~  * HBV seropositivity allowed (HBsAg+) provided they are closely monitored for evidence of active HBV infection by HBV DNA testing~ * After completing treatment, HBsAg + patients must be monitored by HBV DNA testing every 2 months for 6 months post-treatment, while continuing lamivudine (required)~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or immunotherapy (e.g., monoclonal antibody-based therapy) for NHL~  * Prior involved-field radiation therapy allowed~* More than 2 weeks since prior corticosteroids except for maintenance therapy for a non-malignant disease~  * No concurrent dexamethasone or other steroids as antiemetics~* No live virus vaccination within 6 weeks prior to study entry~* No concurrent zidvoudine or stavudine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
- Arm II (Type: EXPERIMENTAL): Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.

Based on this trial design, predict the completion outcome and termination type (if applicable).